Showing results (31-40 of 354) with videos related to
Sort By:
Pageof 36
Cancer Prevention Research (Philadelphia, Pa.)|April 1, 2010
Unprecedented opportunities and promise for cancer prevention researchElizabeth H Blackburn, Thea D Tlsty, Scott M LippmanExpert Opinion on Therapeutic Targets|January 14, 2012
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyLibero Santarpia, Scott M Lippman, Adel K El-NaggarTopics in Current Chemistry|August 2, 2012
Natural-agent mechanisms and early-phase clinical developmentJanet L Wang, Kathryn A Gold, Scott M LippmanHeart Failure Clinics|July 14, 2011
A historical perspective of anthracycline cardiotoxicityMichael S Ewer, Daniel D Von Hoff, Robert S BenjaminCardio-Oncology (London, England)|February 3, 2021
Cardiac safety of afatinib: a review of data from clinical trialsMichael S Ewer, Kalpesh Patel, Dennis O'Brien, et al.Journal of the National Cancer Institute|April 10, 2016
The Conundrum of Genetic "Drivers" in Benign ConditionsShumei Kato, Scott M Lippman, Keith T Flaherty, et al.Molecular Cancer Therapeutics|November 9, 2005
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cellsLinda C Hsi, Xiaopei Xi, Yuanqing Wu, et al.Genome Medicine|February 19, 2020
The paradox of cancer genes in non-malignant conditions: implications for precision medicineJacob J Adashek, Shumei Kato, Scott M Lippman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Cardiac Safety of Osimertinib: A Review of DataMichael S Ewer, Sri Harsha Tekumalla, Andrew Walding, et al.Cardio-Oncology (London, England)|September 18, 2020
An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020Anecita P Fadol, Nicolas L Palaskas, Michael S Ewer, et al.Pageof 36